Australia - English - Department of Health (Therapeutic Goods Administration)

integral surgical pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

integral surgical pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

integral surgical pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - carbon dioxide, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 35044 - electrode, electrosurgical, active, hand-controlled, single use - an electrical conductor intended to provide an electrical connection (possibly in conjunction with a cable) between the output terminals of an electrosurgical generator and a patient at which an electrosurgical effect is intended. the electric power switch for this device is an integral part of the electrode, allowing its operation by the surgeon's hands. this device is typically in the form of a pen or pencil and is often referred to as one of these. this device is single use.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 2513.6 microgram (equivalent: fentanyl, qty 1600 microgram) - lozenge with integral application - excipient ingredients: citric acid; starch sodium octenyl succinate; dextrates; dibasic sodium phosphate; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1885.2 microgram (equivalent: fentanyl, qty 1200 microgram) - lozenge with integral application - excipient ingredients: starch sodium octenyl succinate; dibasic sodium phosphate; dextrates; citric acid; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 1256.8 microgram (equivalent: fentanyl, qty 800 microgram) - lozenge with integral application - excipient ingredients: citric acid; dibasic sodium phosphate; starch sodium octenyl succinate; dextrates; magnesium stearate; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 942.6 microgram (equivalent: fentanyl, qty 600 microgram) - lozenge with integral application - excipient ingredients: starch sodium octenyl succinate; dextrates; magnesium stearate; dibasic sodium phosphate; citric acid; shellac; brilliant blue fcf; maize starch; sucrose; flavour - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 628.4 microgram (equivalent: fentanyl, qty 400 microgram) - lozenge with integral application - excipient ingredients: dibasic sodium phosphate; magnesium stearate; starch sodium octenyl succinate; dextrates; citric acid; shellac; brilliant blue fcf; flavour; maize starch; sucrose - actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.